Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases.
Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that management will present at the RBC Capital Markets Global Healthcare...
– Announced positive two-year topline results of sevasemten ARCH open label trial and advanced GRAND CANYON pivotal cohort in Becker – – Positive interim topline data for DUNE trial of sevasemten...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 1.44 | 8.00444691495 | 17.99 | 19.81 | 17.51 | 831476 | 18.90566692 | CS |
4 | 2.07 | 11.9239631336 | 17.36 | 19.81 | 15.87 | 705908 | 17.60356519 | CS |
12 | 3.13 | 19.2024539877 | 16.3 | 21.6 | 14.9 | 655202 | 17.72333124 | CS |
26 | 9.51 | 95.8669354839 | 9.92 | 21.6 | 9 | 837238 | 16.33568524 | CS |
52 | 11.93 | 159.066666667 | 7.5 | 21.6 | 5.12 | 566393 | 13.93191218 | CS |
156 | -1 | -4.89476260401 | 20.43 | 24.3 | 5.12 | 341830 | 13.00360431 | CS |
260 | -7.57 | -28.037037037 | 27 | 40.49 | 5.12 | 332044 | 13.82470181 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.